

**COMPANY REGISTRATION NUMBER: 10903647**

**ATLANTIC PROTEINS LIMITED**

**UNAUDITED STATEMENT OF ACCOUNTS**

**31 AUGUST 2018**



**ATLANTIC PROTEINS LIMITED**

**CONTENTS**

	<b>PAGE</b>
DIRECTORS REPORT	<b>1</b>
BALANCE SHEET	<b>2</b>
NOTES TO THE STATEMENT OF ACCOUNTS	<b>3 - 4</b>

**ATLANTIC PROTEINS LIMITED**

**DIRECTORS REPORT**  
**YEAR ENDED 31 AUGUST 2018**

The directors present their report and the unaudited Statement of Accounts of the company for the year ended 31 August 2018.

The company has been dormant as defined in section 1169 of the Companies Act 2006 throughout the year. It is anticipated that the company will remain dormant for the foreseeable future.

**DIRECTORS**


The directors who served the company during the year were as follows:

MARTIN POINTON  
CARL POINTON

**SMALL COMPANY PROVISIONS**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

This report was approved by the board of directors on 31 August 2018 and signed on behalf of the board by:

X 

MARTIN POINTON  
Director

**ATLANTIC PROTEINS LIMITED**

**BALANCE SHEET**  
**31 AUGUST 2018**

	<b><u>Note</u></b>	<b><u>2018</u></b>	
		<b>£</b>	<b>£</b>
<b><u>CURRENT ASSETS</u></b>			
Cash at bank and in hand		120	
		<hr/> 120	
<b><u>NET CURRENT ASSETS</u></b>			120
<b><u>TOTAL ASSETS LESS CURRENT LIABILITIES</u></b>			<hr/> 120
<b><u>NET ASSETS</u></b>			<hr/> <hr/> 120
<b><u>CAPITAL AND RESERVES</u></b>			
Called up share capital			120
<b><u>SHAREHOLDERS FUNDS</u></b>			<hr/> <hr/> 120

The company did not trade during the current year or prior year and has not made either a profit or loss.  
For the year ending 31 August 2018 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its Statement of Accounts for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of Statement of Accounts.

These Statement of Accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These Statement of Accounts were approved by the board of directors and authorised for issue on 31 August 2018, and are signed on behalf of the board by:



MARTIN POINTON  
Director

Company registration number: 10903647

**The notes on pages 3 to 4 form part of these Statement of Accounts.**

## **ATLANTIC PROTEINS LIMITED**

### **NOTES TO THE STATEMENT OF ACCOUNTS** **YEAR ENDED 31 AUGUST 2018**

#### **1. GENERAL INFORMATION**

The company is a private company limited by shares, registered in ENGLAND. The address of the registered office is ATLANTIC PROTEINS LIMITED, 45 GILDREDGE ROAD, SUITE 11, EASTBOURNE, EAST SUSSEX, BN21 5PE.

#### **2. STATEMENT OF COMPLIANCE**

These Statement of Accounts have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

#### **3. ACCOUNTING POLICIES**

##### **Basis of preparation**

The Statement of Accounts have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The Statement of Accounts are prepared in sterling, which is the functional currency of the entity.

##### **Income statement policy**

The company is dormant as defined by section 1169 of the Companies Act 2006. The company received no income and incurred no expenditure during the current year.

##### **Taxation**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

**ATLANTIC PROTEINS LIMITED**

**NOTES TO THE STATEMENT OF ACCOUNTS (CONTINUED)**  
**YEAR ENDED 31 AUGUST 2018**

**Financial instruments**

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

**Debtors**

Trade and Other Debtors are measured at transaction price, less any impairment.

**Creditors**

Creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.